Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBAOTCMKTS:BSEMNASDAQ:IMNMNASDAQ:PRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$3.53+3.1%$2.33$0.80▼$3.64$928.68M0.883.00 million shs2.09 million shsBSEMBioStem Technologies$12.45+16.4%$11.66$6.77▼$28.26$207.97M-0.167,283 shs142,602 shsIMNMImmunome$9.41+1.6%$7.73$5.15▼$16.81$818.87M1.94913,477 shs133,309 shsPRAXPraxis Precision Medicines$41.90+1.7%$35.71$26.70▼$91.83$853.60M2.6384,398 shs55,562 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+5.23%+17.12%+39.59%+84.37%+200.00%BSEMBioStem Technologies+16.36%+8.66%-11.26%-3.34%+58.60%IMNMImmunome+2.21%+7.67%+4.63%-0.54%-36.53%PRAXPraxis Precision Medicines+3.47%+14.13%+2.39%+8.85%-12.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKBAAkebia Therapeutics4.1377 of 5 stars4.61.00.04.02.90.00.6BSEMBioStem TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AIMNMImmunome2.9951 of 5 stars4.52.00.00.02.32.50.0PRAXPraxis Precision Medicines2.8225 of 5 stars4.42.00.00.02.71.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 3.20Buy$6.7591.49% UpsideBSEMBioStem Technologies 0.00N/AN/AN/AIMNMImmunome 3.00Buy$23.33147.96% UpsidePRAXPraxis Precision Medicines 2.80Moderate Buy$109.90162.32% UpsideCurrent Analyst Ratings BreakdownLatest BSEM, IMNM, PRAX, and AKBA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.006/2/2025PRAXPraxis Precision MedicinesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$97.005/13/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$33.00 ➝ $21.005/7/2025PRAXPraxis Precision MedicinesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.005/5/2025PRAXPraxis Precision MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetUnderperform ➝ Underperform$26.00 ➝ $28.005/5/2025PRAXPraxis Precision MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/1/2025PRAXPraxis Precision MedicinesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$105.00 ➝ $105.004/28/2025AKBAAkebia TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025AKBAAkebia TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$7.004/8/2025PRAXPraxis Precision MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$85.00 ➝ $85.004/4/2025AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.50 ➝ $7.50(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$184.91M5.01N/AN/A($0.16) per share-22.03BSEMBioStem Technologies$16.68M12.47N/AN/AN/A∞IMNMImmunome$10.94M74.86N/AN/A$2.77 per share3.40PRAXPraxis Precision Medicines$8.12M105.07N/AN/A$7.92 per share5.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$51.92M-$0.21N/AN/AN/A-27.07%N/A-20.57%8/14/2025 (Estimated)BSEMBioStem TechnologiesN/A$1.4718.315.44N/AN/AN/AN/A8/11/2025 (Estimated)IMNMImmunome-$106.81M-$3.18N/AN/AN/A-3,014.59%-48.63%-41.62%8/11/2025 (Estimated)PRAXPraxis Precision Medicines-$123.28M-$10.72N/AN/AN/A-9,409.22%-54.86%-50.52%8/12/2025 (Estimated)Latest BSEM, IMNM, PRAX, and AKBA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q4 2024BSEMBioStem Technologies$1.25$0.17-$1.08$0.17$101.20 million$72.53 million5/12/2025Q1 2025IMNMImmunome-$0.66-$0.52+$0.14-$0.52$0.46 million$2.93 million5/8/2025Q1 2025AKBAAkebia Therapeutics-$0.03$0.03+$0.06$0.03$44.88 million$57.34 million5/2/2025Q1 2025PRAXPraxis Precision Medicines-$3.20-$3.29-$0.09-$3.29$0.20 millionN/A3/19/2025Q4 2024IMNMImmunome-$0.68-$0.84-$0.16-$1.28$3.07 million$2.74 million3/13/2025Q4 2024AKBAAkebia Therapeutics-$0.05-$0.10-$0.05-$0.10$37.36 million$46.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/ABSEMBioStem TechnologiesN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia TherapeuticsN/A1.521.21BSEMBioStem TechnologiesN/AN/AN/AIMNMImmunomeN/A6.176.17PRAXPraxis Precision MedicinesN/A10.9610.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%BSEMBioStem TechnologiesN/AIMNMImmunome44.58%PRAXPraxis Precision Medicines67.84%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.00%BSEMBioStem TechnologiesN/AIMNMImmunome8.60%PRAXPraxis Precision Medicines2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430262.64 million209.24 millionOptionableBSEMBioStem TechnologiesN/A16.70 millionN/AN/AIMNMImmunome4087.01 million72.92 millionOptionablePRAXPraxis Precision Medicines11020.37 million18.14 millionOptionableBSEM, IMNM, PRAX, and AKBA HeadlinesRecent News About These CompaniesPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Sold by Wellington Management Group LLPJune 4 at 4:23 AM | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Holdings Reduced by Squarepoint Ops LLCJune 4 at 3:54 AM | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Rating of "Moderate Buy" by AnalystsJune 3 at 1:37 AM | americanbankingnews.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJune 3 at 1:33 AM | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Coverage Initiated by Analysts at OppenheimerJune 2 at 10:21 AM | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Stock Price Down 5.6% - Time to Sell?June 1 at 3:59 AM | americanbankingnews.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Stock Position Reduced by BNP Paribas Financial MarketsJune 1 at 3:28 AM | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Trading Down 5.6% - Should You Sell?May 31, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Trading 4.3% Higher - Should You Buy?May 30, 2025 | marketbeat.comPolar Asset Management Partners Inc. Makes New Investment in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)May 28, 2025 | marketbeat.com9,948 Shares in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Purchased by Woodline Partners LPMay 28, 2025 | marketbeat.comVoloridge Investment Management LLC Buys 40,875 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)May 27, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Purchased by Millennium Management LLCMay 26, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Position Boosted by VR Adviser LLCMay 22, 2025 | marketbeat.comVelan Capital Investment Management LP Sells 50,666 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)May 21, 2025 | marketbeat.comSoleus Capital Management L.P. Sells 15,858 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)May 21, 2025 | marketbeat.comNorthern Trust Corp Raises Stock Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)May 19, 2025 | marketbeat.com98,617 Shares in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Acquired by Polar Asset Management Partners Inc.May 18, 2025 | marketbeat.comEnsign Peak Advisors Inc Buys New Stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)May 18, 2025 | marketbeat.comNicholas Investment Partners LP Takes Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)May 17, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Purchased by Janus Henderson Group PLCMay 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBSEM, IMNM, PRAX, and AKBA Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$3.52 +0.11 (+3.07%) As of 10:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.BioStem Technologies OTCMKTS:BSEM$12.45 +1.75 (+16.36%) As of 06/3/2025 03:58 PM EasternBioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.Immunome NASDAQ:IMNM$9.41 +0.15 (+1.62%) As of 10:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Praxis Precision Medicines NASDAQ:PRAX$41.90 +0.70 (+1.69%) As of 10:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Microsoft Stock Near Peak, Pullback Seen as Opportunity 3 Reasons Amazon Could Be the Best Tech Performer in June 3 Tech Stocks Insiders Are Buying: Speculative Plays for June Tesla’s Lofty 200 P/E Could Mean More Upside Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
